Cargando…
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037441/ https://www.ncbi.nlm.nih.gov/pubmed/29461919 http://dx.doi.org/10.1080/21645515.2018.1442162 |
_version_ | 1783338330375585792 |
---|---|
author | Schwarz, Tino F. Volpe, Stephanie Catteau, Gregory Chlibek, Roman David, Marie Pierre Richardus, Jan Hendrik Lal, Himal Oostvogels, Lidia Pauksens, Karlis Ravault, Stephanie Rombo, Lars Sonder, Gerard Smetana, Jan Heineman, Thomas Bastidas, Adriana |
author_facet | Schwarz, Tino F. Volpe, Stephanie Catteau, Gregory Chlibek, Roman David, Marie Pierre Richardus, Jan Hendrik Lal, Himal Oostvogels, Lidia Pauksens, Karlis Ravault, Stephanie Rombo, Lars Sonder, Gerard Smetana, Jan Heineman, Thomas Bastidas, Adriana |
author_sort | Schwarz, Tino F. |
collection | PubMed |
description | Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post-initial vaccination. Methods: This open extension study (NCT02735915) followed 70 participants who received two HZ/su doses in the initial trial (NCT00434577). Blood samples to assess the cellular (intracellular cytokine staining) and humoral (ELISA) immunity were taken at year nine post-initial vaccination. Results: Participants' mean age at dose 1 was 72.3 years. The fold increases over pre-vaccination in the mean frequency of gE-specific CD4+ T-cells expressing ≥2 activation markers plateaued from year four post-dose 1 until year nine. Anti-gE antibody geometric mean concentrations plateaued and remained above pre-vaccination levels from year four onwards. Immunogenicity at year nine was similar across age strata (60–69, ≥70 years) and confirmed statistical prediction model results using data for up to year six. Further modeling using all data up to year nine predicted immune responses would remain above the pre-vaccination level up to year 15. Conclusion: In adults aged ≥60 years, HZ/su-induced immunogenicity remained above pre-vaccination levels for at least nine years post-initial vaccination. Summary: After vaccination with HZ/su, both cell mediated and humoral immunity remained above pre-vaccination levels up to year 9 regardless of age group. Immune responses are predicted to remain above baseline up to 15 years post initial vaccination. |
format | Online Article Text |
id | pubmed-6037441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-60374412018-07-11 Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults Schwarz, Tino F. Volpe, Stephanie Catteau, Gregory Chlibek, Roman David, Marie Pierre Richardus, Jan Hendrik Lal, Himal Oostvogels, Lidia Pauksens, Karlis Ravault, Stephanie Rombo, Lars Sonder, Gerard Smetana, Jan Heineman, Thomas Bastidas, Adriana Hum Vaccin Immunother Research Paper Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post-initial vaccination. Methods: This open extension study (NCT02735915) followed 70 participants who received two HZ/su doses in the initial trial (NCT00434577). Blood samples to assess the cellular (intracellular cytokine staining) and humoral (ELISA) immunity were taken at year nine post-initial vaccination. Results: Participants' mean age at dose 1 was 72.3 years. The fold increases over pre-vaccination in the mean frequency of gE-specific CD4+ T-cells expressing ≥2 activation markers plateaued from year four post-dose 1 until year nine. Anti-gE antibody geometric mean concentrations plateaued and remained above pre-vaccination levels from year four onwards. Immunogenicity at year nine was similar across age strata (60–69, ≥70 years) and confirmed statistical prediction model results using data for up to year six. Further modeling using all data up to year nine predicted immune responses would remain above the pre-vaccination level up to year 15. Conclusion: In adults aged ≥60 years, HZ/su-induced immunogenicity remained above pre-vaccination levels for at least nine years post-initial vaccination. Summary: After vaccination with HZ/su, both cell mediated and humoral immunity remained above pre-vaccination levels up to year 9 regardless of age group. Immune responses are predicted to remain above baseline up to 15 years post initial vaccination. Taylor & Francis 2018-03-21 /pmc/articles/PMC6037441/ /pubmed/29461919 http://dx.doi.org/10.1080/21645515.2018.1442162 Text en © 2018 GalxoSmithKline Biologicals SA. Published with license by Taylor & Francis http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Schwarz, Tino F. Volpe, Stephanie Catteau, Gregory Chlibek, Roman David, Marie Pierre Richardus, Jan Hendrik Lal, Himal Oostvogels, Lidia Pauksens, Karlis Ravault, Stephanie Rombo, Lars Sonder, Gerard Smetana, Jan Heineman, Thomas Bastidas, Adriana Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults |
title | Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults |
title_full | Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults |
title_fullStr | Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults |
title_full_unstemmed | Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults |
title_short | Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults |
title_sort | persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037441/ https://www.ncbi.nlm.nih.gov/pubmed/29461919 http://dx.doi.org/10.1080/21645515.2018.1442162 |
work_keys_str_mv | AT schwarztinof persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT volpestephanie persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT catteaugregory persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT chlibekroman persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT davidmariepierre persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT richardusjanhendrik persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT lalhimal persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT oostvogelslidia persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT pauksenskarlis persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT ravaultstephanie persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT rombolars persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT sondergerard persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT smetanajan persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT heinemanthomas persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults AT bastidasadriana persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults |